AU2237395A - Human interleukin variants generated by alternative splicing - Google Patents

Human interleukin variants generated by alternative splicing

Info

Publication number
AU2237395A
AU2237395A AU22373/95A AU2237395A AU2237395A AU 2237395 A AU2237395 A AU 2237395A AU 22373/95 A AU22373/95 A AU 22373/95A AU 2237395 A AU2237395 A AU 2237395A AU 2237395 A AU2237395 A AU 2237395A
Authority
AU
Australia
Prior art keywords
exon
seq
human
mrna
pcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22373/95A
Other languages
English (en)
Inventor
William Alms
Barbara White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of AU2237395A publication Critical patent/AU2237395A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU22373/95A 1994-03-30 1995-03-30 Human interleukin variants generated by alternative splicing Abandoned AU2237395A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21983194A 1994-03-30 1994-03-30
US219831 1994-03-30
US22401094A 1994-04-06 1994-04-06
PCT/US1995/004094 WO1995027052A1 (fr) 1994-03-30 1995-03-30 Variantes d'interleukine humaine generees par epissage de remplacement
US224010 1998-12-31

Publications (1)

Publication Number Publication Date
AU2237395A true AU2237395A (en) 1995-10-23

Family

ID=26914296

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22373/95A Abandoned AU2237395A (en) 1994-03-30 1995-03-30 Human interleukin variants generated by alternative splicing

Country Status (5)

Country Link
EP (1) EP0775202A4 (fr)
JP (1) JPH09511400A (fr)
AU (1) AU2237395A (fr)
CA (1) CA2186854A1 (fr)
WO (1) WO1995027052A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3948495B2 (ja) 1995-08-24 2007-07-25 ジェネーラ コーポレーション 喘息および関連疾患を含むアトピー性アレルギーを治療するための標的としての喘息関連因子
FR2775984B1 (fr) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US5986059A (en) 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins

Also Published As

Publication number Publication date
CA2186854A1 (fr) 1995-10-12
EP0775202A1 (fr) 1997-05-28
EP0775202A4 (fr) 1999-07-14
WO1995027052A1 (fr) 1995-10-12
JPH09511400A (ja) 1997-11-18

Similar Documents

Publication Publication Date Title
Alms et al. Generation of a variant of human interleukin-4 by alternative splicing
JP2568394B2 (ja) 哺乳動物インターロイキン−４活性を示すポリペプチドをコードするヌクレオチド配列からなる核酸
Kikutani et al. Molecular structure of human lymphocyte receptor for immunoglobulin E
Atamas et al. An alternative splice variant of human IL-4, IL-4 delta 2, inhibits IL-4-stimulated T cell proliferation.
CA2125763C (fr) Homodimere p40 de l'interleukine-12
AU760224B2 (en) Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
JP4804529B2 (ja) リンパ球化学誘引因子およびその用途
US5319071A (en) Soluble interleukin-1 receptors
IE61563B1 (en) Interleukin-1 receptors
EP0571442A1 (fr) Proteine tsg-14 induite par la cytokine, adn codant cette proteine et ses utilisations
IE911771A1 (en) Type ii interleukin-1 receptors
WO1994004680A9 (fr) Interleukine-13 humaine
JPH07508179A (ja) ヒトインターロイキン−１３
CA2293735A1 (fr) Variants de lag-3 obtenus par epissage
Yutaka et al. Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: involvement of dithiol related reduction
Karlen et al. Biological and molecular characteristics of interleukin-5 and its receptor
US6040426A (en) Human Th2 specific protein
EP0629130A1 (fr) Utilisation d'interleukine-10 pour supprimer des maladies provoquees par la reaction du greffon contre l'hote
JPH064674B2 (ja) ヒトインタ−ロイキン−１遺伝子のクロ−ニング及び特性化
AU2237395A (en) Human interleukin variants generated by alternative splicing
Hasegawa et al. Monoclonal antibodies to epitope of CD45R (B220) inhibit interleukin 4-mediated B cell proliferation and differentiation
US5766943A (en) DNA sequences for soluble form of CD23
Hattori et al. Generation of continuous large granular lymphocyte lines by interleukin 2 from the spleen cells of mice infected with Moloney leukemia virus. Involvement of interleukin 3.
Kato et al. Induction of IL-2 receptor expression and proliferation of T cell clones by a novel cytokine (s)
Lenz et al. Feγ-receptor III (CD16) is involved in NK-8 cell interaction